Breaking News Instant updates and real-time market news.

2021-02-22 07:27:33 CPT Camden Property $105.23 / +1.4 (+1.35%) 07:27 02/22/21 02/22 07:27 02/22/21 07:27	Camden Property downgraded to Sector Weight on valuation at KeyBanc As previously reported, KeyBanc analyst Austin Wurschmidt downgraded Camden Property to Sector Weight from Overweight as the stock is approaching his prior price target and appears more fairly valued. The analyst continues to expect improving fundamental trends to drive a reacceleration in same store revenue growth in mid to late 2021 and potential upside to guidance. Moreover, Sunbelt demand trends from in-migration and attractive job growth remain positive for Camden Property's medium to longer term growth story, he adds. However, Wurschmidt argues that new supply and a strong single-family housing market could be modest headwinds. Notably, the analyst would look to be opportunistic to the extent fundamentals reaccelerate greater than he is underwriting or the stock pulls back to a more attractive level.	24 Feb
CPT Camden Property $105.23 / +1.4 (+1.35%) 02/21/21 KeyBanc Camden Property downgraded to Sector Weight from Overweight at KeyBanc 02/09/21 BofA Camden Property downgraded to Neutral from Buy at BofA 02/09/21 Baird Camden Property upgraded to Outperform from Neutral at Baird 11/10/20 Mizuho Camden Property downgraded to Neutral from Buy at Mizuho

2021-02-22 07:27:33

CPT

Camden Property

$105.23 / +1.4 (+1.35%)

07:27

02/22/21

02/22

07:27

02/22/21

07:27

Camden Property downgraded to Sector Weight on valuation at KeyBanc

As previously reported, KeyBanc analyst Austin Wurschmidt downgraded Camden Property to Sector Weight from Overweight as the stock is approaching his prior price target and appears more fairly valued. The analyst continues to expect improving fundamental trends to drive a reacceleration in same store revenue growth in mid to late 2021 and potential upside to guidance. Moreover, Sunbelt demand trends from in-migration and attractive job growth remain positive for Camden Property's medium to longer term growth story, he adds. However, Wurschmidt argues that new supply and a strong single-family housing market could be modest headwinds. Notably, the analyst would look to be opportunistic to the extent fundamentals reaccelerate greater than he is underwriting or the stock pulls back to a more attractive level.

24
Feb

CPT Camden Property

$105.23 / +1.4 (+1.35%)

02/21/21 KeyBanc: Camden Property downgraded to Sector Weight from Overweight at KeyBanc

02/09/21 BofA: Camden Property downgraded to Neutral from Buy at BofA

02/09/21 Baird: Camden Property upgraded to Outperform from Neutral at Baird

11/10/20 Mizuho: Camden Property downgraded to Neutral from Buy at Mizuho

TODAY'S FREE FLY STORIES

Downgrade	GPT Group downgraded to Hold from Buy at Jefferies » 08:18 03/05/21 03/05 08:18 03/05/21 08:18 GPTGF GPT Group $0.00 / + (+0.00%) Jefferies analyst Sholto… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GPTGF GPT Group $0.00 / + (+0.00%) 10/29/20 Jefferies GPT Group downgraded to Hold from Buy at Jefferies 06/09/20 Jefferies GPT Group downgraded to Hold from Buy at Jefferies
Upgrade	Seres Therapeutics upgraded to Buy from Neutral at Chardan » 08:17 03/05/21 03/05 08:17 03/05/21 08:17 MCRB Seres Therapeutics $18.01 / +0.395 (+2.24%) Chardan analyst Gbola… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events MCRB Seres Therapeutics $18.01 / +0.395 (+2.24%) 03/02/21 Seres Therapeutics gets target enrollment in SER-287 Phase 2b ECO-RESET study 01/19/21 Seres Therapeutics to present new SER-109 data at Keystone Symposium 01/06/21 Seres Therapeutics publishes data from Phase 1b trial of SER-287 for UC 11/06/20 Seres Therapeutics doses first patient in SER-301 trial MCRB Seres Therapeutics $18.01 / +0.395 (+2.24%) 01/12/21 Piper Sandler Additional Seres '109 analysis strengthens BLA filing, says Piper Sandler 12/23/20 JMP Securities Seres Therapeutics initiated with a Market Perform at JMP Securities 11/09/20 Oppenheimer Seres Therapeutics price target raised to $38 from $34 at Oppenheimer 11/09/20 Piper Sandler Seres Therapeutics price target raised to $49 from $40 at Piper Sandler MCRB Seres Therapeutics $18.01 / +0.395 (+2.24%) 03/02/21 Seres Therapeutics reports Q4 net loss $18.3M versus $18.8M in Q419 11/09/20 Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c) 13 Aug 03/16/21 31st Annual Healthcare Virtual Conference
Downgrade	Lendlease Group downgraded to Hold from Buy at Jefferies » 08:17 03/05/21 03/05 08:17 03/05/21 08:17 LLESY Lendlease Group $0.00 / + (+0.00%) Jefferies analyst Sholto… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research LLESY Lendlease Group $0.00 / + (+0.00%) 11/26/20 Credit Suisse Lendlease Group downgraded to Neutral from Outperform at Credit Suisse 07/07/20 JPMorgan Lendlease Group downgraded to Neutral from Overweight at JPMorgan 03/23/20 Macquarie Lendlease Group downgraded to Neutral from Outperform at Macquarie
Recommendations	Tapestry price target raised to $45 from $36 at BMO Capital » 08:16 03/05/21 03/05 08:16 03/05/21 08:16 TPR Tapestry $40.75 / -0.81 (-1.95%) BMO Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options TPR Tapestry $40.75 / -0.81 (-1.95%) 03/04/21 Tapestry's Kate Spade announces new structure for creative organization 02/04/21 Tapestry sees increase in demand for key categories as vaccine rollout continues 02/04/21 Tapestry sees Covid-related headwinds persisting in near-term 02/04/21 Tapestry 'optimistic' about potential for Kate Spade brand TPR Tapestry $40.75 / -0.81 (-1.95%) 02/22/21 Credit Suisse Tapestry upgraded to Outperform with $50 target at Credit Suisse 02/22/21 Credit Suisse Tapestry upgraded to Outperform from Neutral at Credit Suisse 02/16/21 Piper Sandler Tapestry price target raised to $45 from $42 at Piper Sandler 02/09/21 Telsey Advisory Tapestry upgraded to Outperform from Market Perform at Telsey Advisory TPR Tapestry $40.75 / -0.81 (-1.95%) 02/04/21 Tapestry sees FY21 revenue growth in high-single digits, consensus $5.3B 02/04/21 Tapestry reports Q2 non-GAAP EPS $1.15, consensus $1.01 02/03/21 Notable companies reporting before tomorrow's open 02/03/21 Notable companies reporting before tomorrow's open TPR Tapestry $40.75 / -0.81 (-1.95%) 02/22/21 Airbnb, Snap upgrades among today's top calls on Wall Street 02/04/21 Fly Intel: Pre-market Movers 11/16/20 Verizon resumption, Tapestry upgrade among today's top calls on Wall Street 10/06/20 Beyond Meat boosted by Piper Sandler teen survey results TPR Tapestry $40.75 / -0.81 (-1.95%) 02/25/21 Tapestry put volume heavy and directionally bearish 11/30/20 Tapestry put volume heavy and directionally bearish 10/19/20 Tapestry call volume above normal and directionally bullish 09/16/20 Unusually active option classes on open September 16th
Hot Stocks	ChannelAdvisor to join Google Partners International Growth program » 08:15 03/05/21 03/05 08:15 03/05/21 08:15 ECOM ChannelAdvisor $21.38 / -1.68 (-7.29%) , GOOG Alphabet $2,049.59 / +23.6 (+1.16%) , GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) ChannelAdvisor (ECOM) has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ECOM GOOG GOOGL ECOM ChannelAdvisor $21.38 / -1.68 (-7.29%) 09/28/20 ChannelAdvisor COO Segovia sells over $158K in shares GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 03/03/21 Google backs plan to remove support for third-party cookies in Chrome 02/25/21 MongoDB expands integration of Atlas database with Google Cloud 02/25/21 Schrodinger expands collaboration with Google Cloud 02/24/21 Sterling National Bank collaborates with Google Pay GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 03/03/21 Google backs plan to remove support for third-party cookies in Chrome 02/25/21 Schrodinger expands collaboration with Google Cloud 02/24/21 Sterling National Bank collaborates with Google Pay 02/23/21 Google integrates Password Checkup into Android devices ECOM GOOG GOOGL ECOM ChannelAdvisor $21.38 / -1.68 (-7.29%) 02/12/21 B. Riley Securities ChannelAdvisor price target raised to $36 from $30 at B. Riley Securities 02/09/21 B. Riley Securities ChannelAdvisor price target raised to $30 from $24.50 at B. Riley Securities 11/05/20 Baird ChannelAdvisor price target lowered to $18 from $20 at Baird 10/16/20 Fly Intel: Top five analyst upgrades GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 03/03/21 Jefferies Google Cloud traction under Kurian 'under-appreciated,' says Jefferies 02/17/21 Morgan Stanley Roku price target raised to $275 from $200 at Morgan Stanley 02/12/21 Citi Citi boosts Alphabet target but shares no longer a top pick 02/08/21 Stephens Global Payments merchant business advanced by Google pact, says Stephens GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 03/03/21 Jefferies Google Cloud traction under Kurian 'under-appreciated,' says Jefferies 02/17/21 Maxim Kaleyra price target raised to $30 from $22 at Maxim 02/17/21 Morgan Stanley Roku price target raised to $275 from $200 at Morgan Stanley 02/16/21 Loop Capital Alphabet upgraded to Buy from Hold at Loop Capital ECOM GOOG GOOGL ECOM ChannelAdvisor $21.38 / -1.68 (-7.29%) 02/11/21 ChannelAdvisor sees Q1 revenue $37.3M-$37.7M, consensus $34.95M 02/11/21 ChannelAdvisor reports Q4 EPS 20c, consensus 22c 11/05/20 ChannelAdvisor sees Q4 revenue $37.3M-$38.3M, consensus $37.28M 11/05/20 ChannelAdvisor reports Q3 non-GAAP EPS 20c, consensus 18c GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet 02/02/21 Alphabet reports Q4 EPS $22.30, consensus $15.90 02/02/21 Notable companies reporting after market close 10/29/20 Alphabet reports Q3 Traffic Acquisition Costs $8.17B vs. $7.49B a year ago GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet 02/02/21 Alphabet reports Q4 EPS $22.30, consensus $15.90 02/02/21 Notable companies reporting after market close 10/29/20 Alphabet CFO sees signs user behavior beginning to return to normalized level GOOG GOOGL GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 06:13 Today Trade Desk challenging Google in digital-advertising tech world, WSJ reports 06:01 Today YouTube to lift Trump's suspension when risk of violence drops, CNBC reports 03/04/21 Microsoft president Smith to testify at 'Big Tech' antitrust hearing, Axios says 03/03/21 Apple and Alphabet may hindered by new Arizona app payment rules. Verge says GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 06:13 Today Trade Desk challenging Google in digital-advertising tech world, WSJ reports 06:01 Today YouTube to lift Trump's suspension when risk of violence drops, CNBC reports 03/03/21 Infosys wins $500M all-digital deal from Google, The Economic Times says 02/28/21 Reliance partners with Google, Facebook for payment network bid, Reuters says GOOG GOOGL GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 03/02/21 Game On: GameStop CFO resigns, EA ceases new development on 'Anthem' 02/24/21 #SocialStocks: Snap shares advance following first investor day 02/24/21 Fly Intel: What to watch in Nvidia earnings report 02/23/21 Game On: An exclusive talk with Skeleton Crew's Olsson and Murakami GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 03/02/21 Game On: GameStop CFO resigns, EA ceases new development on 'Anthem' 02/24/21 #SocialStocks: Snap shares advance following first investor day 02/24/21 Fly Intel: What to watch in Nvidia earnings report 02/23/21 Game On: An exclusive talk with Skeleton Crew's Olsson and Murakami 03/17/21 Technology 03/17/21 ChannelAdvisor GOOG GOOGL GOOG Alphabet $2,049.59 / +23.6 (+1.16%) 02/02/21 Alphabet options imply 6.6% move in share price post-earnings 11/10/20 Alphabet call volume above normal and directionally bullish 10/30/20 Early notable gainers among liquid option names on October 30th GOOGL Alphabet Class A $2,034.31 / +24.26 (+1.21%) 02/03/21 Early notable gainers among liquid option names on February 3rd 01/20/21 Early notable gainers among liquid option names on January 20th 10/30/20 Early notable gainers among liquid option names on October 30th 10/21/20 Unusually active option classes on open October 21st

General news	Employment Situation Nonfarm Payrolls to be reported at 08:30 » 08:15 03/05/21 03/05 08:15 03/05/21 08:15 February Employment… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
General news	Employment Situation Unemployment Rate to be reported at 08:30 » 08:15 03/05/21 03/05 08:15 03/05/21 08:15 February Employment… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
General news	International Trade in Goods and Services Balance to be reported at 08:30 » 08:15 03/05/21 03/05 08:15 03/05/21 08:15 January International… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Earnings	Turtle Beach reports Q4 adjusted EPS 84c, consensus 78c » 08:14 03/05/21 03/05 08:14 03/05/21 08:14 HEAR Turtle Beach $28.46 / -0.79 (-2.70%) Last night reported Q4… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HEAR Turtle Beach $28.46 / -0.79 (-2.70%) 01/13/21 Turtle Beach acquires Neat Microphones, terms not disclosed 11/19/20 Turtle Beach and TIdal music platform expand partnership 10/16/20 Video game hardware spending rose 15% year-over-year in September, says NPD HEAR Turtle Beach $28.46 / -0.79 (-2.70%) 02/12/21 Maxim Turtle Beach price target raised to $42 from $28 at Maxim 02/11/21 Stifel Turtle Beach price target raised to $38 from $23.50 at Stifel 02/11/21 DA Davidson Turtle Beach price target raised to $38 from $31 at DA Davidson 02/11/21 Lake Street Turtle Beach price target raised to $40 from $30 at Lake Street HEAR Turtle Beach $28.46 / -0.79 (-2.70%) 03/04/21 Turtle Beach sees Q1 adjusted EPS 45c, consensus 1c 03/04/21 Turtle Beach sees FY21 adjusted EPS $1.35, consensus $1.41 03/04/21 Turtle Beach reports Q4 adjusted EPS 984c, consensus 78c 02/10/21 Turtle Beach sees Q4 adjusted EPS 73c-82c, consensus 47c HEAR Turtle Beach $28.46 / -0.79 (-2.70%) 09/29/20 Fly Intel: After-Hours Movers 03/15/21 33rd Annual Roth Virtual Conference
Hot Stocks	Seagen recommends shareholders reject TRC Capital mini-tender offer » 08:13 03/05/21 03/05 08:13 03/05/21 08:13 SGEN Seagen $145.18 / -2.72 (-1.84%) Seagen announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SGEN Seagen $145.18 / -2.72 (-1.84%) 02/18/21 Astellas, Pharma Seagen submit two sBLAs to FDA for Padcev 02/12/21 Seagen, Astellas Pharma announce results from PADCEV pivotal trial 02/12/21 Seagen's Tukysa approved by European Commission for breast cancer 02/11/21 Seagen sees FY21 ADCETRIS sales $675M-$700M SGEN Seagen $145.18 / -2.72 (-1.84%) 02/16/21 RBC Capital Seagen price target lowered to $169 from $186 at RBC Capital 02/12/21 Barclays Seagen price target lowered to $168 from $177 at Barclays 02/12/21 Piper Sandler Seagen price target lowered to $170 from $175 at Piper Sandler 02/01/21 RBC Capital Seagen downgraded to Sector Perform at RBC Capital on valuation SGEN Seagen $145.18 / -2.72 (-1.84%) 02/11/21 Seagen reports Q4 EPS 90c, consensus 86c 10/29/20 Seagen reports Q3 EPS $3.50 vs. (55c) last year SGEN Seagen $145.18 / -2.72 (-1.84%) 02/11/21 Fly Intel: After-Hours Movers 10/29/20 Fly Intel: After-Hours Movers 09/14/20 Fly Intel: Wall Street's top stories for Monday 09/14/20 Fly Intel: Pre-market Movers 04/09/21 Pharma/Biopharma

Earnings	Hurco Companies reports Q1 EPS 10c vs. (13c) last year » 08:12 03/05/21 03/05 08:12 03/05/21 08:12 HURC Hurco Companies $30.85 / -0.95 (-2.99%) Reports Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Earnings Events HURC Hurco Companies $30.85 / -0.95 (-2.99%) 01/08/21 Hurco Companies reports Q4 EPS (54c) vs. 31c last year 03/11/21 Hurco Companies Inc.
Recommendations	Jamf Holding price target raised to $49 from $45 at RBC Capital » 08:12 03/05/21 03/05 08:12 03/05/21 08:12 JAMF Jamf Holding $36.45 / -1.33 (-3.52%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events JAMF Jamf Holding $36.45 / -1.33 (-3.52%) 03/01/21 Jamf acquires security, compliance solutions created by cmdSecurity 02/01/21 Jamf Holding COO, CFO sell 60.7K shares and 6.3K shares in common stock 01/04/21 Jamf Holding announces it is running on more than 20M Apple devices 11/16/20 Tiger Global adds Snowflake, GSX and BigCommerce during Q3 JAMF Jamf Holding $36.45 / -1.33 (-3.52%) 06:39 Today Mizuho Jamf Holding price target raised to $45 from $43 at Mizuho 01/28/21 Piper Sandler Jamf Holding remains a top idea for 2021 at Piper Sandler 01/05/21 Canaccord Jamf Holding metrics 'bode well' for strong Q4, says Canaccord 09/02/20 Canaccord Jamf Holding upside likely in Q3, says Canaccord JAMF Jamf Holding $36.45 / -1.33 (-3.52%) 03/04/21 Jamf Holding sees FY21 revenue $330M-$336M, consensus $316.41M 03/04/21 Jamf Holding sees Q1 revenue $76M-$77M, consensus $72.44M 03/04/21 Jamf Holding reports Q4 EPS (8c), consensus 1c 19 Nov 22 Jul JAMF Jamf Holding $36.45 / -1.33 (-3.52%) 03/04/21 Fly Intel: After-Hours Movers 03/08/21 Jamf Holding
Recommendations	Market undervaluing Durect's alcoholic hepatitis opportunity, says Chardan » 08:12 03/05/21 03/05 08:12 03/05/21 08:12 DRRX Durect $2.05 / -0.13 (-5.96%) Chardan analyst Michael… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events DRRX Durect $2.05 / -0.13 (-5.96%) 03/04/21 Durect in discussions with potential partners for Posimir 03/04/21 Durect discontinues Covid trial due to lack of patients, other treatments 02/02/21 Durect announces FDA approval of POSIMIR 02/02/21 Durect jumps over 40% after FDA posts approval of pain drug DRRX Durect $2.05 / -0.13 (-5.96%) 02/03/21 Jefferies Posimir should not be significant threat to Pacira's Exparel, says Jefferies 02/03/21 Chardan Chardan boosts Durect target to $8 with 'final overhang' removed 02/02/21 Oppenheimer Posimir approval a 'significant positive' for Durect, says Oppenheimer 02/02/21 Roth Capital Roth reiterates $7 target on Durect after 'surprise' FDA approval DRRX Durect $2.05 / -0.13 (-5.96%) 03/04/21 Durect reports Q4 cont ops EPS (4c), consensus (3c) 11/02/20 Durect reports Q3 EPS (5c), consensus (4c) 04 Feb DRRX Durect $2.05 / -0.13 (-5.96%) 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 03/16/21 31st Annual Healthcare Virtual Conference
Hot Stocks	Virgin Galactic down 7% after Palihapitiya sells 6.2M shares » 08:11 03/05/21 03/05 08:11 03/05/21 08:11 SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) Chamath Palihapitiya,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 02/25/21 Virgin Galactic CFO Jon Campagna to step down, Doug Ahrens to succeed 02/25/21 Virgin Galactic announces leadership appointments 02/22/21 Virgin Galactic hires Joe Rohde as advisor and 'first Experience Architect' 02/18/21 Virgin Galactic move higher attributed to flight test speculation SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 03/03/21 BofA Virgin Galactic price target raised to $50 from $35 at BofA 02/26/21 Alembic Global Virgin Galactic downgraded to Neutral from Overweight at Alembic Global 02/26/21 UBS Virgin Galactic price target lowered to $40 from $52 at UBS 02/09/21 UBS Virgin Galactic downgraded to Neutral from Buy at UBS SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 02/25/21 Virgin Galactic reports Q4 EPS (31c) consensus (31c) 11/05/20 Virgin Galactic reports Q3 EPS (34c), consensus (26c) 06 Aug 03 Jun 20 May SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 02/18/21 Virgin Galactic tells Seeking Alpha launch speculation 'not true' 02/11/21 Virgin Galactic cites 'good progress' to CNBC after FAA posts notice 10/20/20 Chanos 'joking' when talking 'positively' about space companies, CNBC says SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 02/26/21 Fly Intel: Wall Street's top stories for Friday 02/26/21 Fly Intel: Wall Street's top stories at midday 02/26/21 Fly Intel: Pre-market Movers 02/25/21 Fly Intel: After-Hours Movers SPCE Virgin Galactic $30.29 / -1.72 (-5.37%) 02/18/21 Virgin Galactic call volume above normal and directionally bullish 01/29/21 Virgin Galactic call volume above normal and directionally bullish 01/27/21 Virgin Galactic call volume above normal and directionally bullish 01/26/21 Virgin Galactic call volume above normal and directionally bullish
Hot Stocks	Huntington Ingalls appoints Kari Wilkinson as president, Shipbuilding division » 08:11 03/05/21 03/05 08:11 03/05/21 08:11 HII Huntington Ingalls $179.32 / -3.55 (-1.94%) Huntington Ingalls… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options HII Huntington Ingalls $179.32 / -3.55 (-1.94%) 02/26/21 Huntington Ingalls awarded up to $213.9M government contract 02/19/21 Huntington Ingalls awarded $2.99B Navy contract 02/11/21 Huntington Ingalls sees FY21 shipbuilding revenue $8.2B-$8.4B 02/03/21 PMC Capital acquires UniversalPegasus International from Huntington Ingalls HII Huntington Ingalls $179.32 / -3.55 (-1.94%) 01/06/21 Vertical Research Huntington Ingalls downgraded to Hold from Buy at Vertical Research 12/04/20 Alembic Global Huntington Ingalls upgraded to Overweight from Neutral at Alembic Global 10/02/20 JPMorgan Huntington Ingalls price target lowered to $175 from $205 at JPMorgan 10/01/20 Barclays Huntington Ingalls price target lowered to $160 from $190 at Barclays HII Huntington Ingalls $179.32 / -3.55 (-1.94%) 02/11/21 Huntington Ingalls reports Q4 adjusted EPS $4.35, consensus $4.56 11/05/20 Huntington Ingalls sees 2020 shipbuilding revenue $7.9B 11/05/20 Huntington Ingalls reports Q3 EPS $5.45, consensus $4.13 HII Huntington Ingalls $179.32 / -3.55 (-1.94%) 02/11/21 Early notable gainers among liquid option names on February 11th

Hot Stocks	Hanesbrands appoints Tracy Preston general counsel, chief compliance officer » 08:11 03/05/21 03/05 08:11 03/05/21 08:11 HBI Hanesbrands $18.44 / -0.35 (-1.86%) HanesBrands announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options HBI Hanesbrands $18.44 / -0.35 (-1.86%) 02/24/21 Hanesbrands' Champion brand in multi-year pact with the G.O.A.T. 02/10/21 Hanesbrands announces primary licensing pact with Ohio State University 02/09/21 Hanesbrands rises 21.2% 02/09/21 Hanesbrands rises 21.7% HBI Hanesbrands $18.44 / -0.35 (-1.86%) 02/10/21 B. Riley Securities Hanesbrands price target raised to $22 from $19 at B. Riley Securities 02/10/21 Barclays Hanesbrands price target raised to $26 from $16 at Barclays 01/21/21 Deutsche Bank Hanesbrands price target raised to $16 from $14 at Deutsche Bank 12/14/20 Fly Intel: Top five analyst downgrades HBI Hanesbrands $18.44 / -0.35 (-1.86%) 02/09/21 Hanesbrands sees adjusted EPS 24c-27c, consensus 18c 02/09/21 Hanesbrands reports Q4 adjusted EPS 38c, consensus 29c 02/08/21 Notable companies reporting before tomorrow's open 02/08/21 Notable companies reporting before tomorrow's open HBI Hanesbrands $18.44 / -0.35 (-1.86%) 02/09/21 Fly Intel: Pre-market Movers 11/05/20 Fly Intel: Wall Street's top stories for Thursday 11/05/20 Fly Intel: Wall Street's top stories at midday 11/05/20 Fly Intel: Pre-market Movers HBI Hanesbrands $18.44 / -0.35 (-1.86%) 02/09/21 Post-earnings call buyer slips into Hanesbrands March 21s 02/09/21 Early notable gainers among liquid option names on February 9th
Recommendations	Purple Innovation price target lowered to $32 from $38 at Wedbush » 08:09 03/05/21 03/05 08:09 03/05/21 08:09 PRPL Purple Innovation $24.42 / -11.76 (-32.50%) Wedbush analyst Seth… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PRPL Purple Innovation $24.42 / -11.76 (-32.50%) 03/04/21 Purple Innovation: Guidance 'true,' QTD not tracking better than guidance 10/19/20 Purple Innovation signs exclusive partnership with Sleep Country Canada PRPL Purple Innovation $24.42 / -11.76 (-32.50%) 08:05 Today Raymond James Purple Innovation price target lowered to $32 from $36 at Raymond James 06:21 Today UBS Purple Innovation price target lowered to $32 from $44 at UBS 01/12/21 B. Riley Securities Purple Innovation price target raised to $41 from $20 at B. Riley Securities 01/12/21 Wedbush Purple Innovation price target raised to $38 from $32 at Wedbush PRPL Purple Innovation $24.42 / -11.76 (-32.50%) 03/04/21 Purple Innovation sees Q1 revenue $160M-$170M, consensus $176.46M 03/04/21 Purple Innovation sees FY21 revenue $840M-$880M, consensus 03/04/21 Purple Innovation reports Q4 adjusted EPS 7c, consensus 11c 11/11/20 Notable companies reporting after market close 10 Sep 15 May PRPL Purple Innovation $24.42 / -11.76 (-32.50%) 11/10/20 Fly Intel: After-Hours Movers 09/10/20 Fly Intel: Pre-market Movers 09/09/20 Fly Intel: After-Hours Movers PRPL Purple Innovation $24.42 / -11.76 (-32.50%) 12/24/20 Purple Innovation call volume above normal and directionally bullish 12/07/20 Unusual call flow in option market yesterday 12/04/20 Unusual call volume in Purple Innovation as shares traded up 4% 12/01/20 Largest borrow rate increases among liquid names
Hot Stocks	Second Sight receives FDA approval for Argus 2s Retinal Prosthesis System » 08:09 03/05/21 03/05 08:09 03/05/21 08:09 EYES Second Sight $1.43 / -0.29 (-16.86%) Second Sight announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate EYES Second Sight $1.43 / -0.29 (-16.86%) 09/22/20 Second Sight resumes early feasibility study of Orion at UCLA EYES Second Sight $1.43 / -0.29 (-16.86%) 04/01/20 H.C. Wainwright Second Sight rating placed under review at H.C. Wainwright 01 May
Hot Stocks	Brickell Biotech to host KOL webinar on the hyperhidrosis market » 08:08 03/05/21 03/05 08:08 03/05/21 08:08 BBI Brickell Biotech $1.17 / + (+0.00%) Brickell Biotech… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events BBI Brickell Biotech $1.17 / + (+0.00%) 01/19/21 Brickell announces Japan Phase 3 study results for sofpironium bromide gel 12/07/20 Brickell Biotech doses first patient in second U.S. Phase 3 study 11/18/20 Brickell Biotech announces Japan launch date for sofpironium bromide gel, 5% 10/06/20 Brickell Biotech initiates U.S. Phase 3 program of sofpironium bromide gel, 15% BBI Brickell Biotech $1.17 / + (+0.00%) 09/25/20 Lake Street Approval in Japan validating for Brickell Biotech, says Lake Street 08/28/20 Lake Street Brickell Biotech initiated with a Buy at Lake Street 08/25/20 Oppenheimer Brickell Biotech initiated with an Outperform at Oppenheimer 23 Oct 18 Jun 03/10/21 Global Life Sciences Virtual Conference 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 31st Annual Healthcare Virtual Conference 03/09/21 Brickell Biotech - BBI
Hot Stocks	Fathom acquires real estate brokerage business of Red Barn Real Estate » 08:08 03/05/21 03/05 08:08 03/05/21 08:08 FTHM Fathom $34.78 / -5.22 (-13.05%) Fathom Holdings announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate FTHM Fathom $34.78 / -5.22 (-13.05%) 02/16/21 Fathom, Zavvie partner for residential real estate service 02/10/21 Fathom signs agreement to acquire technology platform Naberly Solutions 11/05/20 Fathom to acquire Verus Title, terms not disclosed FTHM Fathom $34.78 / -5.22 (-13.05%) 02/10/21 Roth Capital Roth raises Fathom target to $52, sees 'multifold benefits' from Naberly deal 02/09/21 DA Davidson Fathom initiated with a Buy at DA Davidson 01/25/21 Roth Capital Fathom price target raised to $50 from $40 at Roth Capital 12/28/20 Roth Capital Fathom price target raised to $40 from $28 at Roth Capital 28 Jul

Hot Stocks	Immutep expands Part B of TACTI-002 Phase II study » 08:07 03/05/21 03/05 08:07 03/05/21 08:07 IMMP Immutep $2.41 / -0.2 (-7.66%) Immutep is pleased to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly IMMP Immutep $2.41 / -0.2 (-7.66%) 01/27/21 Immutep announces DSMB recommends Phase II trial advance with enrollment 01/21/21 Immutep announces GlaxoSmithKline discontinuation of GSK2831781 trial 01/06/21 Immutep completes recruitment in TACTI-002 phase 3 study trial 12/29/20 Immutep secures U.S. patent for Eftilagimod Alpha IMMP Immutep $2.41 / -0.2 (-7.66%) 01/26/21 Alliance Global Partners Immutep price target raised to $6 from $5 at Alliance Global Partners 12/14/20 Maxim Maxim doubled Immutep price target after breast cancer update 11/11/20 Maxim Immutep price target raised to $4 from $2 at Maxim 09/22/20 Top five analyst initiations IMMP Immutep $2.41 / -0.2 (-7.66%) 12/30/20 Fly Intel: Pre-market Movers 12/29/20 Fly Intel: After-Hours Movers
Recommendations	Joint Corp. price target raised to $54 from $28 at Maxim » 08:07 03/05/21 03/05 08:07 03/05/21 08:07 JYNT Joint Corp. $44.28 / -4.77 (-9.72%) Maxim analyst Anthony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events JYNT Joint Corp. $44.28 / -4.77 (-9.72%) 01/05/21 Joint Corp. acquires two regional developer territories for $2.4M JYNT Joint Corp. $44.28 / -4.77 (-9.72%) 02/25/21 B. Riley Securities Joint Corp. price target raised to $47 from $26 at B. Riley Securities 01/06/21 Craig-Hallum Joint Corp. price target raised to $38 from $26 at Craig-Hallum 01/04/21 Lake Street Joint Corp. price target raised to $35 from $25 at Lake Street 11/06/20 B. Riley Securities Joint Corp. price target raised to $26 from $22 at B. Riley Securities JYNT Joint Corp. $44.28 / -4.77 (-9.72%) 03/04/21 Joint Corp. sees FY21 revenue $73M-$77M , consensus $72.23M 03/04/21 Joint Corp. reports Q4 EPS 72c, consensus 14c 11/05/20 Joint Corp. reports Q3 EPS 11c, consensus 2c 03/15/21 33rd Annual Roth Virtual Conference
Hot Stocks	Allied Esports confirms proposal from Bally's to acquire the company for $100M » 08:07 03/05/21 03/05 08:07 03/05/21 08:07 AESE Allied Esports Entertainment $3.27 / +0.77 (+30.80%) , BALY Bally's $52.30 / -8.27 (-13.65%) Allied Esports… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events AESE BALY AESE Allied Esports Entertainment $3.27 / +0.77 (+30.80%) 08:00 Today Allied Esports Entertainment Inc trading halted, news dissemination 01/19/21 Allied Esports Entertainment sells World Poker Tour to Element Partners 01/13/21 Allied Esports, HyperX renew naming rights agreement for HyperX Esports Arena 12/17/20 Allied Esports Entertainment, Trovo announce battle royale Esports tournament BALY Bally's $52.30 / -8.27 (-13.65%) 03/04/21 Bally's becomes authorized sports betting operator of the NBA 03/04/21 Bally's CEO seeing 'markedly stronger consumer demand' in January, February 02/22/21 Bally's submits proposal to develop casino in Richmond, Virginia 02/18/21 Bally's becomes official sports betting partner of The National Hockey League AESE BALY AESE Allied Esports Entertainment $3.27 / +0.77 (+30.80%) 06/08/20 Alliance Global Partners Alliance Global says Allied Esports refinancing eliminates near-term overhang 05/15/20 Stephens Allied Esports Entertainment price target lowered to $4 from $5 at Stephens 05/06/20 Alliance Global Partners Allied Esports Entertainment initiated with a Buy at Alliance Global Partners BALY Bally's $52.30 / -8.27 (-13.65%) 06:55 Today Stifel Stifel upgrades Bally's to Buy after 'overplayed' post-earnings dip 05:30 Today Stifel Bally's upgraded to Buy from Hold at Stifel 02/24/21 Truist Bally's price target raised to $80 from $65 at Truist 02/09/21 Stifel Bally's price target raised to $60 from $50 at Stifel BALY BALY Bally's $52.30 / -8.27 (-13.65%) 03/04/21 Bally's reports Q4 adjusted EPS 39c, consensus (8c) 11/09/20 Bally's Corporation changes name from Twin River Worldwide Holdings BALY BALY Bally's $52.30 / -8.27 (-13.65%) 01/21/21 Japan expects Tokyo Olympics will have to be cancelled, The Times says AESE BALY AESE Allied Esports Entertainment $3.27 / +0.77 (+30.80%) 02/01/21 Fly Insider:Allied Esports,Applied Optoelectronics among notable insider trades BALY Bally's $52.30 / -8.27 (-13.65%) 02/26/21 Bet On It: Florida and Texas trying to get in on the action 02/19/21 Bet On It: Penn National's lack of promotional spend sets it apart 02/12/21 Bet On It: Texas and Hawaii face opposition to legalized sports betting 02/05/21 Bet On It: Georgia online sports betting bill passes first test 03/15/21 33rd Annual Roth Virtual Conference
Recommendations	Outfront Media price target raised to $24 from $22 at Barrington » 08:07 03/05/21 03/05 08:07 03/05/21 08:07 OUT Outfront Media $21.47 / -0.305 (-1.40%) Barrington analyst James… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings Syndicate On The Fly OUT Outfront Media $21.47 / -0.305 (-1.40%) 03/02/21 Citi Outfront Media price target raised to $25 from $21 at Citi 11/12/20 Citi Outfront Media price target raised to $21 from $18 at Citi 11/02/20 Morgan Stanley Lamar Advertising upgraded at Morgan Stanley with recovery not priced in 09/25/20 Citi Outfront Media upgraded to Buy from Neutral at Citi OUT Outfront Media $21.47 / -0.305 (-1.40%) 02/25/21 Outfront Media reports Q4 EPS (2c), consensus (3c) 11/04/20 Outfront Media reports Q3 adjusted EPS (14c), consensus (18c) 23 Feb OUT Outfront Media $21.47 / -0.305 (-1.40%) 09/25/20 Fly Intel: Pre-market Movers
Hot Stocks	Keros presents results from preclinical studies of KER-050, ALK2 Inhibitors » 08:06 03/05/21 03/05 08:06 03/05/21 08:06 KROS Keros Therapeutics $55.16 / -2.32 (-4.04%) Keros Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly KROS Keros Therapeutics $55.16 / -2.32 (-4.04%) 12/21/20 Keros Therapeutics added to the Nasdaq Biotechnology Index 12/17/20 Keros Therapeutics appoints Mary Ann Gray to board of directors 12/07/20 Keros Therapeutics presents results from ALK2 Inhibitor program 10/20/20 Keros Therapeutics doses first participants in Phase 2 trial of KER-050 KROS Keros Therapeutics $55.16 / -2.32 (-4.04%) 12/08/20 SVB Leerink Keros Therapeutics price target raised to $80 from $42 at SVB Leerink 12/08/20 H.C. Wainwright Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright 12/08/20 Piper Sandler Keros Therapeutics price target raised to $95 from $75 at Piper Sandler 11/18/20 Piper Sandler Keros Therapeutics price target raised to $75 from $55 at Piper Sandler 13 Nov 08 Apr KROS Keros Therapeutics $55.16 / -2.32 (-4.04%) 11/13/20 Fly Intel: Pre-market Movers

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

International Trade in Goods Balance: January 2021 Government Event
Today at 08:30

Manufacturing Payrolls M/M: February 2021 Government Event
Today at 08:30

Employment Situation--Participation Rate: February 2021 Government Event
Today at 08:30

Employment Situation--Average Hourly Earnings M/M: February 2021 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: February 2021 Government Event
Today at 08:30

Employment Situation--Average Hourly Earnings Y/Y: February 2021 Government Event
Today at 08:30

Employment Situation--Unemployment Rate: February 2021 Government Event
Today at 08:30

Employment Situation: Average Workweek: February 2021 Government Event
Today at 08:30

Employment Situation--Private Payrolls M/M: February 2021 Government Event
ONCY
Today at 08:30

Oncolytics - ONCY Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	EYE X EYE National Vision Block Trade Managers: JPMorgan Priced at: $46.50 3.9M Shares INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC Priced at: $28.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson Priced at: $41.00 4.95M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DGII X DGII Digi International Secondary Managers: Piper Sandler Priced at: $19.50 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLRX X SLRX Salarius Pharmaceuticals Secondary Managers: Ladenburg Priced at: $1.3685 14.615M Shares VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities Priced at: $18.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LASR X LASR nLight Spot Secondary Managers: Stifel & Raymond James Priced at: $34.00 2.206M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR Priced at: $11.50 4.35M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STX X STX Seagate Spot Secondary Managers: JPMorgan Priced at: $73.25 4.65M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham Priced at: $31.00 4.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SUI X SUI Sun Communities Secondary Managers: Citi, BofA, BMO Capital, JPMorgan & RBC Capital Priced at: $140.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRC X AMRC Ameresco Spot Secondary Managers: BofA & Oppenheimer, Baird, Canaccord, Guggenheim, William Blair Priced at: $44.00 3.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Camden Property downgraded to Sector Weight on valuation at KeyBanc

TODAY'S FREE FLY STORIES

Get Full Fly Access